# Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Source: https://onco.cc/trials/nct07326566/  
OnCo record `nct07326566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide, Silevertinib in brain and spinal cord tumours, run by Black Diamond Therapeutics, Inc., now recruiting.

## Summary

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII is a phase 2 interventional study registered as NCT07326566 by Black Diamond Therapeutics, Inc., with 162 participants planned, started 2026-05-05 and due to reach its primary completion in 2028-11. Interventions recorded: silevertinib in combination with temozolomide, temozolomide (TMZ). Conditions listed: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07326566
- Phase: 2
- Setting: A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII
- Sponsor: Black Diamond Therapeutics, Inc.
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT07326566: https://clinicaltrials.gov/study/NCT07326566

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Silevertinib](https://onco.cc/drugs/silevertinib/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Black Diamond Therapeutics](https://onco.cc/companies/black-diamond-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07326566.json